Completed PHASE3 INTERVENTIONAL 1-arm NCT00683995

A Phase III Clinical Study of KW-2246

A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients

Sponsor: Kyowa Kirin Co., Ltd.

Interventions KW-2246 (fentanyl citrate)

Updated 8 times since 2017 Last updated: Aug 27, 2020 Started: Mar 31, 2008 Primary completion: Jul 31, 2009 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Pain, Cancer, this trial is completed. The trial is conducted by Kyowa Kirin Co., Ltd. and has accumulated 8 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Aug 2019 — Sep 2020 [monthly]

Completed PHASE3
Jun 2018 — Aug 2019 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kyowa Kirin Co., Ltd.

Data source: Kyowa Kirin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Azumino, Japan , Bunkyo-ku, Japan , Ibaraki, Japan , Izumisano, Japan , Kanazawa, Japan , Kasama, Japan , Katori-shi, Japan , Kitakyushu, Japan , Kumamoto, Japan , Kōriyama, Japan and 10 more locations